Tailoring liposomes for cancer drug delivery : from the bench to the clinic = Préparation de liposomes pour la délivrance de médicaments anticancéreuxGABIZON, A.Annales de biologie clinique (Paris). 1993, Vol 51, Num 9, pp 811-813, issn 0003-3898Conference Paper

REGULATORY ACTION OF THE THF ON T-CELL REACTIVITY TO MITOGENSGABIZON A; TRAININ N.1980; THYMUS; ISSN 0165-6090; NLD; DA. 1980; VOL. 1; NO 4-5; PP. 225-239; BIBL. 21 REF.Article

ENHANCEMENT OF GROWTH OF A RADIATION-INDUCED LYMPHOMA BY T CELLS FROM NORMAL MICEGABIZON A; TRAININ N.1980; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1980; VOL. 42; NO 4; PP. 551-558; BIBL. 29 REF.Article

KINETICS OF THE RESPONSE OF SPLEEN CELLS FROM TUMOR-BEARING ANIMALS IN AN IN VIVO TUMOR NEUTRALIZATION ASSAY.GABIZON A; SMALL M; TRAININ N et al.1976; INTERNATION. J. CANCER; SWITZ.; DA. 1976; VOL. 18; NO 6; PP. 813-819; ABS. FR.; BIBL. 12 REF.Article

E-ROSETTES IN HUMAN LYMPHOCYTES. ENHANCEMENT AND DEPRESSION AFTER INCUBATION OF LYMPHOCYTES WITH PAPAIN AND TRYPSIN.GARRIDO F; GABIZON A; OSORIO C et al.1975; REV. ESP. FISIOL.; ESP.; DA. 1975; VOL. 31; NO 3; PP. 145-149; BIBL. 11 REF.Article

ENHANCEMENT OF E-ROSETTES FORMATION AFTER TREATMENT OF LYMPHOCYTES WITH PAPAIN = AUGMENTATION DE LA FORMATION DE ROSETTESE APRES TRAITEMENT DES LYMPHOCYTES PAR LA PAPAINEGARRIDO F; GABIZON A; OSORIO C et al.1974; REV. ESP. FISIOL.; ESP.; DA. 1974; VOL. 30; NO 4; PP. 303; BIBL. 4REF.Article

Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomesBANDAK, S; RAMU, A; BARENHOLZ, Y et al.Pharmaceutical research. 1999, Vol 16, Num 6, pp 841-846, issn 0724-8741Article

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyGABIZON, A; PERETZ, T; SULKES, A et al.European journal of cancer & clinical oncology. 1989, Vol 25, Num 12, pp 1795-1803, issn 0277-5379, 9 p.Article

Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2CABANES, A; EVEN-CHEN, S; ZIMBEROFF, J et al.Clinical cancer research. 1999, Vol 5, Num 3, pp 687-693, issn 1078-0432Article

Polyethylene glycol-coated (pegylated) liposomal doxorubicin : Rationale for use in solid tumoursGABIZON, A; MARTIN, F.Drugs (Basel). 1997, Vol 54, pp 15-21, issn 0012-6667, SUP4Article

Liposome longevity and stability in circulation : Effects of the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclinesGABIZON, A; CHEMLA, M; TZEMACH, D et al.Journal of drug targeting. 1996, Vol 3, Num 5, pp 391-398, issn 1061-186XArticle

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesGABIZON, A; CATANE, R; UZIELY, B et al.Cancer research (Baltimore). 1994, Vol 54, Num 4, pp 987-992, issn 0008-5472Article

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinomaLYASS, O; UZIELY, B; BEN-YOSEF, R et al.Cancer. 2000, Vol 89, Num 5, pp 1037-1047, issn 0008-543XArticle

The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behaviorGOREN, D; GABIZON, A; BARENHOLZ, Y et al.Biochimica et biophysica acta. 1990, Vol 1029, Num 2, pp 285-294, issn 0006-3002, 10 p.Article

Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour modelGABIZON, A; GOREN, D; FUKS, Z et al.British journal of cancer. 1985, Vol 51, Num 5, pp 681-689, issn 0007-0920Article

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid : pharmacokinetic studies in rodents and dogsGABIZON, A. A; BARENHOLZ, Y; MEIR BIALER et al.Pharmaceutical research. 1993, Vol 10, Num 5, pp 703-708, issn 0724-8741Article

Liposome circulation time and tumor targeting : implications for cancer chemotherapyGABIZON, A. A.Advanced drug delivery reviews. 1995, Vol 16, Num 2-3, pp 285-294, issn 0169-409XArticle

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model : biodistribution and therapeutic efficacySIEGAL, T; HOROWITZ, A; GABIZON, A et al.Journal of neurosurgery. 1995, Vol 83, Num 6, pp 1029-1037, issn 0022-3085Article

In vitro cytotoxicity of liposome-encapsulated doroxubicin dependence on liposome composition and drug releaseHOROWITZ, A. T; BARENHOLZ, Y; GABIZON, A. A et al.Biochimica et biophysica acta. Biomembranes. 1992, Vol 1109, Num 2, pp 203-209, issn 0005-2736Article

Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor modelsGABIZON, A; GOREN, D; BARENHOLZ, Y et al.Israel journal of medical sciences. 1988, Vol 24, Num 9-10, pp 512-517, issn 0021-2180Article

Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administrationGABIZON, A; MESHORER, A; BARENHOLZ, Y et al.Journal of the National Cancer Institute. 1986, Vol 77, Num 2, pp 459-469, issn 0027-8874Article

Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticlesSCHROEDER, J. E; SHWEKY, I; SHMEEDA, H et al.Journal of controlled release. 2007, Vol 124, Num 1-2, pp 28-34, issn 0168-3659, 7 p.Article

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomesSYMON, Z; PEYSER, A; TZEMACH, D et al.Cancer. 1999, Vol 86, Num 1, pp 72-78, issn 0008-543XArticle

Development of liposomal anthracyclines : from basics to clinical applicationsGABIZON, A; GOREN, D; COHEN, R et al.Journal of controlled release. 1998, Vol 53, Num 1-3, pp 275-279, issn 0168-3659Conference Paper

Liposomal doxorubicin : antitumor activity and unique toxicities during two complementary phase I studiesUZIELY, B; JEFFERS, S; ISACSON, R et al.Journal of clinical oncology. 1995, Vol 13, Num 7, pp 1777-1785, issn 0732-183XArticle